KAEDI Biotechnology

Kaedi Biotechnology is a clinical-stage biopharmaceutical company based in Suzhou, China, focused on developing innovative CAR-T cell therapies for the treatment of solid tumors. The company leverages its proprietary KD-SMART technology platform to design chimeric antigen receptors that target a broad range of tumor-associated antigens while enhancing T-cell persistence and infiltration into the tumor microenvironment. Its lead program, KD-025, is a CAR-T therapy targeting NKG2D ligands, currently being investigated in clinical trials for patients with advanced solid malignancies such as colorectal and gastric cancers. Kaedi's pipeline also includes several preclinical and early-stage candidates targeting mesothelin and GPC3, aiming to expand the reach of immunotherapy beyond hematological cancers.